BRIBFOTCHealthcare · Biotechnology

Brii Biosciences Limited

$0.16-17.43%($-0.03)

TickerSpark Score

50/100

Mixed

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BRIBF research report →

52-Week Range0% of range

Low $0.16

Current $0.16

High $0.26

Companywww.briibio.com

Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria.

CEO: Zhi Hong
IPO: 2022
Employees: 98
HQ: Beijing, CN

Price Chart

-40.23% · this period

Valuation

Market Cap: $112.07M
P/E: -3.51
P/S: 39.58
P/B: 0.32
EV/EBITDA: -0.56
Div Yield: 0.00%

Profitability

Gross Margin: 5.15%
Op Margin: -1534.06%
Net Margin: -1124.36%
ROE: -8.92%
ROIC: -12.68%

Growth & Income

Revenue: $18.12M · -63.70%
Net Income: $-216,878,992 · 57.32%
EPS: $-0.30 · 57.14%
Op Income: $-295,905,623
FCF YoY: 23.31%

Performance & Tape

52W High: $0.26
52W Low: $0.16
50D MA: $0.19
200D MA: $0.21
Beta: 1.26
Avg Volume: 2.23K

Get TickerSpark's AI analysis on BRIBF

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime